Contribution of the opioid system to realization of inotropic effcts of rhodiola rosea extracts in ischemic and reperfusion heart damage in vitro

Yu B. Lishmanov, A. V. Naumova, S. A. Afanas'ev, L. N. Maslov

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

It has been established that a course of oral administration of rhodiola rosea extract in a dose of 3.5 mg/kg prevents reperfusion decrease in contraction amplitude of the isolated perfused rat heart. It also prevents reduction of coronary flow and development of contracture in the postischemic period. Intravenous infusion of naloxone (0.5 mg/kg) completely absishes the favorable effect of rhodiola in relation to the heart contractility and coronary flow parameters. The protective effect of rhodiola may probably be connected with increase in the level of endogenous opioid peptides.

Original languageEnglish
Pages (from-to)36
Number of pages1
JournalEksperimental'naya i Klinicheskaya Farmakologiya
Volume60
Issue number3
Publication statusPublished - 1997

Fingerprint

Rhodiola
Reperfusion Injury
Opioid Analgesics
Opioid Peptides
Naloxone
Myocardial Contraction
Rats
Contracture
Intravenous Infusions
Reperfusion
Oral Administration
In Vitro Techniques

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

@article{5c6761c91d9c44119ea0574dbb3848de,
title = "Contribution of the opioid system to realization of inotropic effcts of rhodiola rosea extracts in ischemic and reperfusion heart damage in vitro",
abstract = "It has been established that a course of oral administration of rhodiola rosea extract in a dose of 3.5 mg/kg prevents reperfusion decrease in contraction amplitude of the isolated perfused rat heart. It also prevents reduction of coronary flow and development of contracture in the postischemic period. Intravenous infusion of naloxone (0.5 mg/kg) completely absishes the favorable effect of rhodiola in relation to the heart contractility and coronary flow parameters. The protective effect of rhodiola may probably be connected with increase in the level of endogenous opioid peptides.",
author = "Lishmanov, {Yu B.} and Naumova, {A. V.} and Afanas'ev, {S. A.} and Maslov, {L. N.}",
year = "1997",
language = "English",
volume = "60",
pages = "36",
journal = "Eksperimental'naya i Klinicheskaya Farmakologiya",
issn = "0869-2092",
publisher = "Izdatelstvo Meditsina",
number = "3",

}

TY - JOUR

T1 - Contribution of the opioid system to realization of inotropic effcts of rhodiola rosea extracts in ischemic and reperfusion heart damage in vitro

AU - Lishmanov, Yu B.

AU - Naumova, A. V.

AU - Afanas'ev, S. A.

AU - Maslov, L. N.

PY - 1997

Y1 - 1997

N2 - It has been established that a course of oral administration of rhodiola rosea extract in a dose of 3.5 mg/kg prevents reperfusion decrease in contraction amplitude of the isolated perfused rat heart. It also prevents reduction of coronary flow and development of contracture in the postischemic period. Intravenous infusion of naloxone (0.5 mg/kg) completely absishes the favorable effect of rhodiola in relation to the heart contractility and coronary flow parameters. The protective effect of rhodiola may probably be connected with increase in the level of endogenous opioid peptides.

AB - It has been established that a course of oral administration of rhodiola rosea extract in a dose of 3.5 mg/kg prevents reperfusion decrease in contraction amplitude of the isolated perfused rat heart. It also prevents reduction of coronary flow and development of contracture in the postischemic period. Intravenous infusion of naloxone (0.5 mg/kg) completely absishes the favorable effect of rhodiola in relation to the heart contractility and coronary flow parameters. The protective effect of rhodiola may probably be connected with increase in the level of endogenous opioid peptides.

UR - http://www.scopus.com/inward/record.url?scp=0347801984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347801984&partnerID=8YFLogxK

M3 - Article

VL - 60

SP - 36

JO - Eksperimental'naya i Klinicheskaya Farmakologiya

JF - Eksperimental'naya i Klinicheskaya Farmakologiya

SN - 0869-2092

IS - 3

ER -